Agile Therapeutics Inc.
| NASDAQ: AGRX | Healthcare / Drug Manufacturers / USA |
| 2.02 | -0.0801 | -3.81% | Vol 47.49K | 1Y Perf 588.56% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 2.00 | ASK | 2.20 | ||
| Open | 2.00 | Previous Close | 2.10 | ||
| Pre-Market | - | After-Market | 2.02 | ||
| - - | - -% |
| Target Price | 2.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | -0.99 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★ 37.68 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.58 | Earnings Rating | Buy | |
| Market Cap | 3.89M | Earnings Date | 6th Nov 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.31 | |
| Beta | 1.13 |
Today's Price Range 2.002.20 | 52W Range 1.6516.00 | 5 Year PE Ratio Range -3.50-4.30 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.00% | ||
| 1 Month | -16.33% | ||
| 3 Months | -30.69% | ||
| 6 Months | 833.79% | ||
| 1 Year | 588.56% | ||
| 3 Years | -31.37% | ||
| 5 Years | 438.49% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -81.56 | |||
ROE last 12 Months | -875.51 | |||
ROA (5Y Avg) | -64.73 | |||
ROA last 12 Months | -270.54 | |||
ROC (5Y Avg) | -67.98 | |||
ROC last 12 Months | -356.40 | |||
Return on invested Capital Q | -147.76 | |||
Return on invested Capital Y | -82.48 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 2.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 1.81 | ||||
| 1.76 | ||||
| - | ||||
| -0.30 | ||||
| -4.26 | ||||
| 1.81 | ||||
| 0.15 | ||||
| 7.33M | ||||
| Forward PE | -2.26 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.80 | ||||
| 1.30 | ||||
| 0.08 | ||||
| 0.34 | ||||
| -18.20 | ||||
| Leverage Ratio | 6.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -29.50 | ||||
| -809.20 | ||||
| -785.10 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.89M | ||||
| 0.17 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -3.48 | -3.10 | 10.92 |
| Q01 2023 | - | -7.76 | - |
| Q04 2022 | -10.50 | -9.00 | 14.29 |
| Q03 2022 | -15.00 | -11.50 | 23.33 |
| Q02 2022 | - | -135.50 | - |
| Q01 2022 | - | -189.00 | - |
| Q04 2021 | -340.00 | -400.00 | -17.65 |
| Q03 2021 | -7.60 | -7.20 | 5.26 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -1.58 | 0.00 | - |
| 12/2023 QR | -0.48 | 0.00 | - |
| 12/2023 FY | -6.05 | 0.00 | - |
| 12/2024 FY | -1.06 | 0.00 | - |
| Next Report Date | 6th Nov 2023 |
| Estimated EPS Next Report | -1.58 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 47.49K |
| Shares Outstanding | 1.93K |
| Shares Float | 1.65M |
| Trades Count | 293 |
| Dollar Volume | 97.79K |
| Avg. Volume | 54.51K |
| Avg. Weekly Volume | 66.72K |
| Avg. Monthly Volume | 47.62K |
| Avg. Quarterly Volume | 49.20K |
Agile Therapeutics Inc. (NASDAQ: AGRX) stock closed at 2.1001 per share at the end of the most recent trading day (a -18.92% change compared to the prior day closing price) with a volume of 46.09K shares and market capitalization of 3.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 15 people. Agile Therapeutics Inc. CEO is Alfred Altomari.
The one-year performance of Agile Therapeutics Inc. stock is 588.56%, while year-to-date (YTD) performance is 825.15%. AGRX stock has a five-year performance of 438.49%. Its 52-week range is between 1.65 and 16, which gives AGRX stock a 52-week price range ratio of 2.58%
Agile Therapeutics Inc. currently has a PE ratio of 0.00, a price-to-book (PB) ratio of 1.81, a price-to-sale (PS) ratio of 1.76, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -270.54%, a ROC of -356.40% and a ROE of -875.51%. The company’s profit margin is -%, its EBITDA margin is -785.10%, and its revenue ttm is $6.89 Million , which makes it $0.17 revenue per share.
Of the last four earnings reports from Agile Therapeutics Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.58 for the next earnings report. Agile Therapeutics Inc.’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for Agile Therapeutics Inc. is Strong Buy (1), with a target price of $2, which is -0.99% compared to the current price. The earnings rating for Agile Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Agile Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Agile Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.15, ATR14 : 0.23, CCI20 : 64.17, Chaikin Money Flow : 0.04, MACD : -0.02, Money Flow Index : 63.10, ROC : 0.48, RSI : 48.07, STOCH (14,3) : 47.88, STOCH RSI : 0.44, UO : 54.28, Williams %R : -52.12), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Agile Therapeutics Inc. in the last 12-months were:
Agile Therapeutics Inc.
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.
CEO: Alfred Altomari
Telephone: +1 609 683-1880
Address: 101 Poor Farm Road, Princeton 08540, NJ, US
Number of employees: 15
